Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature
Open Access
- 15 February 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 87 (6), 439-449
- https://doi.org/10.1007/s00277-008-0441-8
Abstract
Gaucher disease type I, the most common lysosomal storage disorder, is associated with immunoglobulin abnormalities. We studied the prevalence, risk factors, pathogenesis, and effect of enzyme relation therapy (ERT) on gammopathies in an adult Gaucher disease type I cohort (N = 63) and related the results to a review of the currently available literature. Polyclonal gammopathies and monoclonal gammopathy of undetermined significance (MGUS) in our adult GD I cohort were found in 41% and 19% of patients. These results are similar to the data from the literature and correspond to the increased risk of multiple myeloma (MM) that has been described. The prevalence of MGUS in our cohort increased with age but was not associated with disease severity or exposure time. The serum levels of free light chains of immunoglobulins were measured and were not found predictive for the development of MGUS or MM. Levels of pro- as well as anti-inflammatory cytokines, growth factors, and chemokines, especially those involved in inflammation and B-cell function, are disturbed in GD I, with the most impressive and consisting elevations for interleukin-10 and pulmonary and activation-regulated chemokine. A beneficial effect of ERT on the occurrence and progression of gammopathies was suggested from longitudinal data.Keywords
This publication has 67 references indexed in Scilit:
- Recommendations for the management of the haematological and onco‐haematological aspects of Gaucher disease1British Journal of Haematology, 2007
- Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood, 2005
- TNF-α levels and TNF-α gene polymorphism in type I Gaucher diseaseCytokine, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Gaucher Cells Demonstrate a Distinct Macrophage Phenotype and Resemble Alternatively Activated MacrophagesAmerican Journal of Clinical Pathology, 2004
- Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic interventionBlood, 2004
- Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10QJM: An International Journal of Medicine, 1997
- Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1996
- Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.JCI Insight, 1994
- GAUCHER'S DISEASE AND BENIGN MONOCLONAL GAMMAPATHYActa Medica Scandinavica, 1975